Skip to Content
Merck
CN

SML1573

Tolrestat

≥98% (HPLC)

Synonym(s):

AY-27773, CID 53359, N-[[5 -(Trifluoromethyl)-6-methoxy-lnaphthalenyl]thioxomethyl]-N-methylglycine, N-[[6-Methoxy-5-(trifluoromethyl)-1-naphthalenyl]thioxomethyl]-N-methyl-glycine, Tolrestatin

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C16H14F3NO3S
CAS Number:
82964-04-3
Molecular Weight:
357.35
UNSPSC Code:
12352200
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

SMILES string

FC(F)(F)c1c2c(c(ccc2)C(=S)N(CC(=O)O)C)ccc1OC

InChI

1S/C16H14F3NO3S/c1-20(8-13(21)22)15(24)11-5-3-4-10-9(11)6-7-12(23-2)14(10)16(17,18)19/h3-7H,8H2,1-2H3,(H,21,22)

InChI key

LUBHDINQXIHVLS-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Biochem/physiol Actions

Tolrestat is considered to be effective in treating the consequences of diabetes including neuropathy, nephropathy, retinopathy and esophageal motility and vibration perception. Tolrestat is also believed to have lesser or no toxic effects.
Tolrestat is an orally active and potent aldose reductase inhibitor. Studies have also shown that it reduces RBC (red blood cells) sorbitol levels in rats.

Storage Class

11 - Combustible Solids

wgk

WGK 3

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000445455
0000445455
0000439069
0000439069
0000117081

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Effect of Tolrestat on oesophageal transit time and cholecystic motility in type 2 diabetic patients with asymptomatic diabetic neuropathy.
Fabiani F, et al.
Diabete & Metabolisme, 21(5), 360-364 (1995)
Principles of diabetes mellitus (2010)
Felicia D'Andrea et al.
Journal of enzyme inhibition and medicinal chemistry, 35(1), 1194-1205 (2020-05-13)
Aldose reductase is a key enzyme in the development of long term diabetic complications and its inhibition represents a viable therapeutic solution for people affected by these pathologies. Therefore, the search for effective aldose reductase inhibitors is a timely and
Susanna Nencetti et al.
Bioorganic & medicinal chemistry, 25(12), 3068-3076 (2017-04-11)
Aldose reductase (ALR2), a NADPH-dependent reductase, is the first and rate-limiting enzyme of the polyol pathway of glucose metabolism and is implicated in the pathogenesis of secondary diabetic complications. In the last decades, this enzyme has been targeted for inhibition

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service